Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    DHAQ (*Diacetate salt*)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 970,398Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Stem cell transplants may slow disability progression in MS
    Stem cell transplants may slow disability progression in MS

    22 Dec 2022

    // Caroline Peachey EUROPEANPHARMACEUTICALREVIEW

    https://www.europeanpharmaceuticalreview.com/news/177879/stem-cell-transplants-may-slow-disability-progression-in-ms/

    Caroline Peachey EUROPEANPHARMACEUTICALREVIEW
    22 Dec 2022
    Share Share
    Teva's troubled plant seen to create injectable drug shortages
    Teva's troubled plant seen to create injectable drug shortages

    24 May 2022

    // Joseph Keenan FIERCEPHARMA

    https://www.fiercepharma.com/manufacturing/tevas-halt-production-troubled-plant-seen-create-shortages-range-injectables

    Joseph Keenan FIERCEPHARMA
    24 May 2022
    Share Share
    Actinium Shows 72% MRD Negativity Rate in Phase 1 Study of Actimab-A + CLAG-M
    Actinium Shows 72% MRD Negativity Rate in Phase 1 Study of Actimab-A + CLAG-M

    14 Dec 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-announces-72-mrd-negativity-rate-in-the-recently-completed-phase-1-study-of-actimab-a-in-combination-with-clag-m-for-patients-with-relapsed-or-refractory-aml-301444015.html

    PRNEWSWIRE
    14 Dec 2021
    Share Share
    Hospira Announces Voluntary Worldwide Recall of 10 Lots of Mitoxantrone Due to Confirmed Subpotency and Out-Of-Specification Impurities
    Hospira Announces Voluntary Worldwide Recall of 10 Lots of Mitoxantrone Due to Confirmed Subpotency and Out-Of-Specification Impurities

    23 Dec 2014

    //

    http://www.fda.gov/Safety/Recalls/ucm427952.htm

    23 Dec 2014
    Share Share